Form 4: Enliven CFO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Enliven Therapeutics CFO Benjamin Hohl exercised stock options and subsequently sold 3,250 shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), reported changes in his beneficial ownership.
- On September 29, 2025, Mr. Hohl exercised 3,250 stock options at an exercise price of $2.48 per share.
- Concurrently, he sold 3,250 shares of common stock at a weighted average price of $20.3973 per share.
- These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following these transactions, Mr. Hohl beneficially owns 23,000 shares of common stock and 105,056 stock options.
Sentiment
Score: 5
Explanation: The filing reports a routine, pre-planned insider transaction under a Rule 10b5-1 plan, which is generally considered neutral in sentiment as it is not a discretionary sale based on new information.
Positives
- The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and non-discretionary sale.
- The sale price of $20.3973 per share is significantly higher than the exercise price of $2.48, indicating a substantial gain for the reporting person.
Negatives
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, though the pre-arranged nature mitigates this.
Risks
- No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Management Comments
- No direct quotes or paraphrased statements from company management are included in this Form 4 filing.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide information relevant to broader industry trends or competitor analysis.
Comparison to Industry Standards
- This filing details an individual insider transaction and does not contain information suitable for comparison to global benchmarks, comparable companies, projects, or results.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 26, 2023. This plan allows insiders to sell shares without concerns about insider trading, provided the plan is established when the insider is not in possession of material non-public information. | 2023-06-26 | Enhances transparency and reduces the perception of opportunistic insider trading by pre-scheduling transactions. |
Legal Proceedings
- No litigation or regulatory matters are mentioned in this filing.
Related Party Transactions
- No related party dealings are disclosed beyond the insider's own transactions.
Stakeholder Impact
- Shareholders may note the insider sale, but the pre-arranged nature under a 10b5-1 plan typically mitigates concerns about discretionary selling.
- No direct impact on employees, customers, suppliers, or creditors is indicated.
Next Steps
- No specific future actions, events, or milestones for the company are mentioned in this filing.
Key Dates
| Date | Description |
|---|---|
| 2023-06-26 | Date Rule 10b5-1 trading plan was adopted by Benjamin Hohl. |
| 2025-09-29 | Date of stock option exercise and subsequent sale of common stock. |
| 2025-10-01 | Signature date of the reporting person on the Form 4 filing. |
| 2031-08-02 | Expiration date of the stock options. |
Keywords
Enliven Therapeutics, ELVN, Benjamin Hohl, CFO, Form 4, insider trading, stock options, 10b5-1 plan, beneficial ownership, equity sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.